FLT3 mutation + NPM1 mutation
|
AML
|
FLT3 mutation + NPM1 mutation
|
AML
|
gilteritinib Sensitive: C3 – Early Trials
|
gilteritinib Sensitive: C3 – Early Trials
|
FLT3 mutation + NPM1 mutation
|
AML
|
FLT3 mutation + NPM1 mutation
|
AML
|
ivosidenib Resistant: C3 – Early Trials
|
ivosidenib Resistant: C3 – Early Trials
|
FLT3 mutation + NPM1 mutation
|
AML
|
FLT3 mutation + NPM1 mutation
|
AML
|
CB-659 Sensitive: D – Preclinical
|
CB-659 Sensitive: D – Preclinical
|
FLT3 mutation + NPM1 mutation
|
AML
|
FLT3 mutation + NPM1 mutation
|
AML
|
ixazomib Resistant: D – Preclinical
|
ixazomib Resistant: D – Preclinical
|